Status:
WITHDRAWN
FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis
Lead Sponsor:
University Hospitals Cleveland Medical Center
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to validate FibroScan and FibroSURE™ as equal or superior alternatives to liver biopsy for the monitoring and detection of methotrexate-induced hepatic fibrosis and cirrho...
Detailed Description
The goals of this study are to validate FibroScan and FibroSURE™ as equal or superior alternatives to liver biopsy. The goal is to evaluate the monitoring and detection of methotrexate-induced hepatic...
Eligibility Criteria
Inclusion
- Male or female greater than or equal to 18 years of age
- Must have a diagnosis of moderate-to-severe psoriasis
- Newly starting methotrexate
Exclusion
- Allergy to methotrexate
- History of chronic alcohol abuse
- Diagnosis of liver disease
Key Trial Info
Start Date :
February 10 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 15 2019
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03820934
Start Date
February 10 2019
End Date
May 15 2019
Last Update
July 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106